Nexalin Technology, Inc. (NXL)

HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding its Gen-2 SYNC™ neurostimulation console for the treatment of Alzheimer's disease. The meeting focused on Nexalin's proposed clinical development plan and overall regulatory strategy for the Gen-2 SYNC console in Alzheimer's disease.

HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin's CEO Mark White, who will provide an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology.

HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-intensity transcranial alternating current stimulation for gambling disorder comorbidities with alcohol use disorders: A case report.” The study evaluated the safety and efficacy of Nexalin's 15 milliamp (mA) neurostimulation device in a patient diagnosed with both gambling disorder (GD) and alcohol use disorder (AUD).

Appointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device Appointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device

HOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the U.S. Food and Drug Administration (“FDA”) has formally accepted its Q-Submission (“Q-Sub”) related to the Company's Gen-2 Console (“SYNC”) system for the treatment of Alzheimer's disease and dementia, with a regulatory meeting scheduled for later this year. This acceptance of the Company's request for interaction with the FDA with respect to its Gen-2 SYNC system represents a significant step toward Nexalin's goal of achieving FDA authorization to begin U.S. clinical studies targeting Alzheimer's and dementia — two of the most urgent unmet needs in healthcare.

MNTN (NYSE: MNTN - Get Free Report) and Nexalin Technology (NASDAQ: NXL - Get Free Report) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Earnings and Valuation This table compares MNTN

HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console (“SYNC”), 15 milliamp (mA) neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health.

HOUSTON, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that three independently published, peer-reviewed clinical studies, coupled with a growing body of internal data, collectively demonstrate the ability of its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer's disease (AD). Each study was announced separately upon publication.

HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year.

HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries.

Nexalin Technology Inc. (NASDAQ:NXL) stock spiked on Wednesday, with a massive session volume of 167.9 million compared to the average volume of 972.2 thousand, as per data from Benzinga Pro.

40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal of the Radiological Society of North America (RSNA) HOUSTON, TX, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—Nexalin's advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease (AD). The randomized, sham-controlled trial provides the strongest peer-reviewed evidence to date of a non-invasive, drug-free intervention delivering measurable neurological and clinical benefits in AD.

HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company's next-generation HALO™ Clarity neuromodulation device.

HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology.

HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.

HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology.